Gebruik van predictieve markers voor targeted therapy in de algemene praktijk



Similar documents
Molecular analyses of EGFR: mutation and amplification detection

Nuevas tecnologías basadas en biomarcadores para oncología

IKDT Laboratory. IKDT as Service Lab (CRO) for Molecular Diagnostics

Corporate Medical Policy

Launching a Cancer Genetic Laboratory to Enhance Diagnosis and Treatment

Targeted Therapy What the Surgeon Needs to Know

How To Get A Cell Print

The Diagnosis of Cancer in the Pathology Laboratory

Introduction To Real Time Quantitative PCR (qpcr)

White paper Evaluation of BRAF (V600E) Mutation by Immunohistochemical Staining with anti-braf V600E (VE1) Antibody: A Comparison with Sanger

ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)

Accurate and sensitive mutation detection and quantitation using TaqMan Mutation Detection Assays for disease research

Molecular Diagnostics in Thyroid Cancer

EARLY ONLINE RELEASE

Overview of Genetic Testing and Screening

micrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved

Evaluation of a Microfluidic System for Performance of Fully Automated Companion Diagnostics for Personalized Medicine

March 19, Dear Dr. Duvall, Dr. Hambrick, and Ms. Smith,

Case based applications part III

PNA BRAF Mutation Detection Kit

CHROMOSOMES Dr. Fern Tsien, Dept. of Genetics, LSUHSC, NO, LA

Targeted. sequencing solutions. Accurate, scalable, fast TARGETED

Molecular Diagnosis of Gastrointestinal Tumors

Breast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns


YOUR LUNG CANCER PATHOLOGY REPORT

Validation parameters: An introduction to measures of

EGFR mutation testing: what is the best choice?

bitter is de pil Linos Vandekerckhove, MD, PhD

Sahlgrenska universitetssjukhuset

Molekylært målrettet medicinsk kræftbehandling for klinikere principper og metoder

Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer

Formalin fixation at low temperature better preserves nucleic acid integrity. Gianni Bussolati. University of Turin

Reimbursement for Molecular Diagnostics

MetAction actionable targets in cancer metastasis from bed to bench to byte to bedside

Molecular Genetics: Challenges for Statistical Practice. J.K. Lindsey

If you are signing for a minor child, you refers to your child throughout the consent document.

What is Cancer? Cancer is a genetic disease: Cancer typically involves a change in gene expression/function:

RENAL CANCER PATHOLOGY WHAT REALLY MATTERS? STEWART FLEMING UNIVERSITY OF DUNDEE

Instruction manual for product # PNAC Version 1.2

El papel de la anatomía patológica en oncología: presente y futuro. The role of pathological anatomy in oncology: present and future

Corporate Medical Policy Molecular Markers in Fine Needle Aspirates of the Thyroid

Analysis of gene expression data. Ulf Leser and Philippe Thomas

Clinical Use of Molecular in the Treatment of Lung Cancer

Craig Hallum Conference Investor Presentation

Moving forward, where are we with Clinical Trials?

Applications of comprehensive clinical genomic analysis in solid tumors: obstacles and opportunities

IKDT Laboratory. IKDT as Service Lab (CRO) for Molecular Diagnostics

Your Guide to the Breast Cancer Pathology Report

Appendix 2 Molecular Biology Core Curriculum. Websites and Other Resources

Practical Effusion Cytology

HER2/neu (erbb2) Analysis on FNA Smears and Core Biopsies of Primary or Metastatic Breast Cancer. Ann Thor M.D.

Data Analysis for Ion Torrent Sequencing

Single-Cell Whole Genome Sequencing on the C1 System: a Performance Evaluation

Independent Validation of the Prognostic Gene Expression Ratio Test in Formalin Fixed, Paraffin Embedded (FFPE) Mesothelioma Tumor Tissue Specimens

Genomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America

Targeted Therapies in Lung Cancer

Validation of BRAF Mutational Analysis in Thyroid Fine Needle Aspirations: A Morphologic- Molecular Approach

Seattle. Case Presentations. Case year old female with a history of breast cancer 12 years ago. Now presents with a pleural effusion.

Robert Bristow MD PhD FRCPC

Oncology Insights Enabled by Knowledge Base-Guided Panel Design and the Seamless Workflow of the GeneReader NGS System

Microsatellite Instability (MSI) A New Paradigm in Cancer Treatment. Lynch Syndrome OUTLINE. GI Molecular Pathology

Laboratory Testing for Her2 Status in Breast Cancer

HER2 Status: What is the Difference Between Breast and Gastric Cancer?

1. Le mutazioni di KRAS hanno tutte lo stesso significato clinico?

ncounter Leukemia Fusion Gene Expression Assay Molecules That Count Product Highlights ncounter Leukemia Fusion Gene Expression Assay Overview

Outline. Workup for metastatic breast cancer. Metastatic breast cancer

High-quality genomic DNA isolation and sensitive mutation analysis

QuantStudio 12K Flex Real-Time PCR System. The all-in-one qpcr instrument

The following chapter is called "Preimplantation Genetic Diagnosis (PGD)".

CONTRACTING ORGANIZATION: University of Alabama at Birmingham Birmingham, AL 35294

Nuovi Scenari in Oncologia. G. Zoppoli X-Files in Nutrizione Clinica e Artificiale, 08/06/2012

The following information is only meant for people who have been diagnosed with advanced non-small cell

Essentials of Real Time PCR. About Sequence Detection Chemistries

Bureau of Laboratory Quality Standards Page 1 of 6

Roche Diagnostics. Daniel O Day COO Roche Diagnostics. Bernstein 8 th Annual Decisions Conference, London September 20, 2011

Consistent Assay Performance Across Universal Arrays and Scanners

Microarray Technology

Translational Technologies Resources (TTR)

Blood based colon cancer screening in Europe. Methylated Septin 9: Biomarker of malignant development in the colon Measured in Tissue and Plasma

microrna Signatures in Cancer E. ROBERT WASSMAN, MD, FAAP, FACMG CHIEF MEDICAL OFFICER, ROSETTA GENOMICS

REPORT PERSPECTIVES IN LUNG CANCER 2010 AMSTERDAM

Reconsideration Code Reconsideration Code Description Nuclear Matrix Protein 22 (NMP22), qualitative

Pharmacogenomic Approaches. Luis Paz-Ares Hospital Universitario Virgen del Rocio Seville, Spain

Individualizing Your Lung Cancer Care: Informing Decisions Through Biomarker Testing

Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma

targeted therapy a guide for the patient

How many of you have checked out the web site on protein-dna interactions?

The Role of Genetic Testing in the Evaluation of Thyroid Nodules. Thyroid Cancer and FNA. Thyroid Cancer. Pure Follicular Cancers.

Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle

PrimePCR Assay Validation Report

A 70-year old Man with Pleural Effusion

AIDS IN IDENTIFYING CANDIDATES FOR HER2-TARGETED THERAPY

Lung Carcinomas New 2015 WHO Classification. Spasenija Savic Pathology

The RNA strategy. RNA as a tool and target in human disease diagnosis and therapy.

SUPER SENSITIVE TM. mirna in FFPE. Next-Gen in situ Tissue Signature Markers Potential tool for Characterization of CUP

Changes in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain

Receptor conversion in distant breast cancer metastases. Breast cancer metastases: A spitting image of their primary?

INTRODUCTION. Chapter One

SICKLE CELL ANEMIA & THE HEMOGLOBIN GENE TEACHER S GUIDE

Transcription:

Gebruik van predictieve markers voor targeted therapy in de algemene praktijk Gerrit A. Meijer, MD, PhD Professor of Pathology Chair of the Department of Pathology VU Universtiy Medical Center Amsterdam The Netherlands www.gameijer.nl www.tumorprofiling.org

Pathology = To collect as much information relevant to the patient as possible from cell and tissue samples

normal adenoma malignant polyp carcinoma

> proliferation < apoptosis < differentitaion < cell cycle ctrl < basal membr. > motility <> extr cell matrix. > stroma > angiogenesis < immune system mutation loss amplification SNP methylation post transcriptional mod.

How to read out tumor biology? http:// microbiology.ucdavis.edu/ sklab/images/dna%20repair %20cartoon.jpg

Carriers of biological information DNA Deletions Amplifications Mutations Structural rearrangements Translocations Epigegenitic changes Promoter hypermethylation LOH, MLPA FISH, CISH, MLPA Sequencing, HRM FISH, RT-PCR MSP

Carriers of biological information: RNA Stelling 1 Uit paraffine materiaal kun je geen goed RNA krijgen.

Carriers of biological information RNA mrna RTPCR, microarray mirna RTPCR, microarray

Carriers of biological information proteins http:// www.researchherpathway s.com/researchherpath/ images/ Section_3-2_detection.jpg

PamChip 144 target peptides porous AlOx slide Mariet Labots, Henk Verheul PamGene, s-hertogenbosch

Logistics Samples Methods

Stelling 2 Hematoxylline-Eosine is de belangrijkste kleuring in het kader van diagnostiek tbv targeted therapy.

Samples Garbage in, garbage out Histological evaluation is mandatory Primary tumor / metastasis What is the target to treat CRC: metastases Are primaries and mets comparable Lung: primary

Stelling 3 Gebrekkige organisatie van de infrastructuur tussen pathologie laboratoria in Nederland belemmert efficiënte uitvoering van diagnostiek tbv targeted therapy.

Samples What is the material available? CRC Lung Primary tumor At least biopsy Often resection Sometimes resection Sometimes minute biopsies with minority of tumor cells Other Metastases Pleural fluid Sputum? Unique infrastructure in NL: PALGA

Samples Fresh frozen Limited availability Sandwich slides mandatory Formaldehyde Fixed Paraffin Embedded (FFPE) Ubiquitous (still) Excellent for DNA tests Excellent for immunohistochemistry

CAIRO 180k arraycgh on FFPE CRC primary tumor tissue Josien Haan, Danielle Israeli,., Bauke Ylstra

Pro Methods Immunohistochemistry Runs at all pathology labs routinely Simple read out: Pahtologist & Microscope Con Not stoichiometric amount of staining amount of protein Depends on Sample handling etc Settings in the lab (detection kits, Ab s) Interpretation

Pro What you see is what you get Con Tecnically demanding Methods In situ hybridization Interpretation not always straightforward Hybridization conditions deteriorate tissue morphology Formal scoring can be time consuming

Pro More black and white Better reproducible Methods sequencing Con Requires dedicated staff and equipment QA/QC is key

High Resolution Melting (HRM) Principle: PCR with inclusion of an intercalating fluorescent dye, with subsequent melting curve analysis. Source: http://www.dna.utah.edu/hi-res

High Resolution Melting (HRM) The melting curve of a PCR product depends on o.a. - GC content - length - sequence - heterozygosity -> Different genetic sequences melt at slightly different rates Comparing the melting curve of a specimen to a reference (wild type) allows scanning for any sequence variation -> Pre-screen assay with possibility to sequence PCR products to confirm genotype

HRM EGFR/K-ras panel Panel of HRM assays to prescreen for mutations: K-ras x1 -> a.o. codon 12/13 K-ras x2 -> a.o. codon 61 EGFR x19 -> a.o. deletions EGFR x20p -> a.o. ins 770/771 EGFR x20d -> a.o. T790M EGFR x21 -> a.o. L858R Kramer et al. 2009 Heideman et al. 2009

Procedure of mutation detection by HRM 1) run cycling and melting program 2) check for correct amplification curves 3) check for melting curves and melting peaks (amplimer area and probe area, if applicable) 4) evaluate normalized, temperature-shifted difference plot (amplimer)

Analytical performance: High analytical sensitivity of HRM and subsequent sequencing example: K-ras exon 1 (G12C) 2.5-5% mutant DNA in a background of wt can be well discriminated from background/noise signal Kramer et al. Cell Oncol 2009

Performance of HRM on DNA isolated from FFPEtissue in comparison to conventional nested-pcr/ sequencing 1. High genotype agreement of HRM following sequencing with conventional nested-pcr following cycle-sequencing (kappa > 0.95) 2. Less-test failures 3. More mutations detected by HRM (likely related to the higher sensitivity as compared to conventional assay) Kramer et al. 2009 Heideman et al. 2009

K-ras: high genotyping agreement of HRM with conventional cycle sequencing assay Kramer et al. 2009

EGFR: high genotyping agreement of HRM with conventional cycle sequencing assay Heideman et al. 2009

Conclusion Increased interest in mutation analysis in MD in PA Current indications (January 2010; may change in time) 1) EGFR x19/x21 -> EGFR-TKI lung cancer 2) K-ras -> contra anti-egfr moab colorectal cancer Novel indications likely (b-raf, PIK3CA,...) Variety of assays available Molecular assay useful in clinical/ diagnostic setting - applicable to routine material (FFPE / cytology) - sensitive: low-abundant mutants detectable - fast and accurate - prescreen technique -> high throughput - allows for genotyping

Stelling 4 Over 10 jaar heeft een patholoog geen microscoop meer nodig op zijn bureau.